EYES stock forecast
Our latest prediction for Second Sight Medical Products, Inc.'s stock price was made on the Dec. 12, 2018 when the stock price was at 0.92$.
In the short term (2weeks), EYES's stock price should outperform the market by 6.36%. During that period the price should oscillate between -8.86% and +19.70%.
In the medium term (3months), EYES's stock price should outperform the market by 7.87%. During that period the price should oscillate between -21.13% and +54.59%.Get email alerts
Create a solid portfolio with EYES
About Second Sight Medical Products, Inc.
Second Sight Medical Products, Inc. engages in the development, manufacture, and marketing of implantable visual prosthetics. It operates through the following geographical segments: United States, Italy, France, and China. The firm's product include Argus II Retinal Prosthesis System that treats outer retinal degenerations, such as retinitis pigmentosa, also referred to as RP. The company was founded by Alfred E. Mann, Aaron Mendelsohn, Sam Williams, Robert J. Greenberg, and Gunnar Bjorg in 1998 and is headquartered in Sylmar, CA.
At the moment the company generates 8M USD in revenues.
On its last earning announcement, the company reported a loss of -0.54$ per share.
The book value per share is 0.09$
Three months stock forecastDec. 12, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|